Abdulrafeh Naqash to Immunotherapy
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Immunotherapy.
Connection Strength
1.177
-
Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol. 2018 05; 57(5):705-708.
Score: 0.536
-
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer. 2019 01 08; 7(1):4.
Score: 0.145
-
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int J Mol Sci. 2018 Nov 07; 19(11).
Score: 0.143
-
Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. Acta Oncol. 2018 06; 57(6):867-872.
Score: 0.134
-
Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. Oncologist. 2022 Sep 02; 27(9):778-789.
Score: 0.047
-
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022 08 15; 128(16):3067-3079.
Score: 0.046
-
Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology. 2022; 11(1):2017162.
Score: 0.045
-
Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. Oncologist. 2021 10; 26(10):e1883-e1886.
Score: 0.044
-
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 02 20; 38(6):576-583.
Score: 0.039